Northwest Biotherapeutics cancer drug test starts in U.K.

Northwest Biotherapeutics Inc., a Bethesda-based biotechnology company focused on improving the body’s immune response to cancer, announced that a Phase III clinical trial of DCVax-L, its flagship treatment for brain cancer, has been initiated at King’s College Hospital in London, England, a major center for neuro-oncology.

Leave a Reply

Your email address will not be published. Required fields are marked *